首站-论文投稿智能助手
典型文献
SNHG16 promotes hepatocellular carcinoma development via activating ECM receptor interaction pathway
文献摘要:
Background: Accumulating data have suggested that long non-coding RNAs (lncRNAs) play important roles in regulating tumor cell growth. This study was designed to investigate the role of SNHG16 in hep- atocellular carcinoma (HCC).Methods: SNHG16 expression was detected with real-time polymerase chain reaction (PCR). The cut- off value of SNHG16 for tumor-free survival (TFS) was determined with receiver operating characteristic curve analysis. Small interfering RNA was used to inhibit the expression of SNHG16 in HCC cell lines. The biologic behavior of HCC cell was determined with cell viability assay and Transwell assay in vitro . The potential predictive value of SNHG16 on prognosis was analyzed by Kaplan-Meier curves and Cox proportional hazards regression model. Results: SNHG16 expression was upregulated in tumor tissues and HCC cell lines. High expression of SNHG16 was associated with tumor recurrence and poor prognosis after surgery. Multivariate analysis revealed that SNHG16 was an independent prognostic factor for poor recurrence-free survival. Moreover, inhibition of SNHG16 in HepG2, Hep3B, and BEL-7402 cells significantly reduced cell invasiveness and proliferation. Mechanistic analyses indicated that the ECM-receptor interaction pathway was remarkably activated by SNHG16. Conclusions: SNHG16 might be a promising biomarker for predicting tumor recurrence in HCC patients after surgery and a potential therapeutic target for HCC.
文献关键词:
作者姓名:
Qi-Jun Zhang;Da-Zhi Li;Bing-Yi Lin;Lei Geng;Zhe Yang;Shu-Seng Zheng
作者机构:
Department of Thyroid Surgery,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;NHC Key Laboratory of Combined Multi-organ Transplantation,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Department of Hepatobiliary and Pancreatic Surgery,Shulan(Hangzhou)Hospital,Zhejiang Shuren University School of Medicine,Hangzhou 310000,China
引用格式:
[1]Qi-Jun Zhang;Da-Zhi Li;Bing-Yi Lin;Lei Geng;Zhe Yang;Shu-Seng Zheng-.SNHG16 promotes hepatocellular carcinoma development via activating ECM receptor interaction pathway)[J].国际肝胆胰疾病杂志(英文版),2022(01):41-49
A类:
atocellular
B类:
SNHG16,promotes,hepatocellular,carcinoma,development,activating,ECM,receptor,interaction,pathway,Background,Accumulating,data,have,suggested,that,long,coding,lncRNAs,play,important,roles,regulating,tumor,growth,This,study,was,designed,investigate,HCC,Methods,expression,detected,real,polymerase,chain,reaction,cut,off,value,free,survival,TFS,determined,receiver,operating,characteristic,analysis,Small,interfering,used,lines,biologic,behavior,viability,assay,Transwell,vitro,potential,predictive,prognosis,analyzed,by,Kaplan,Meier,curves,Cox,proportional,hazards,regression,model,Results,upregulated,tissues,High,associated,recurrence,poor,after,surgery,Multivariate,revealed,independent,prognostic,Moreover,inhibition,HepG2,Hep3B,BEL,cells,significantly,reduced,invasiveness,proliferation,Mechanistic,analyses,indicated,remarkably,activated,Conclusions,might,promising,biomarker,predicting,patients,therapeutic,target
AB值:
0.535629
相似文献
Globular adiponectin-mediated vascular remodeling by affecting the secretion of adventitial-derived tumor necrosis factor-αinduced by urotensin Ⅱ
Jun LI;Limin LUO;Yonggang ZHANG;Xiao DONG;Shuyi DANG;Xiaogang GUO;Wenhui DING-Department of Cardiology,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Division of Cardiology,Department of Internal Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,China;Division of Cardiology,Department of Internal Medicine,Peking University First Hospital,Beijing 100034,China;Department of Dermatology,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Department of Cardiovascular Diseases,the Second Affiliated Hospital,Shantou University Medical College,Shantou 515041,China
Overexpressed NEDD8 as a potential therapeutic target in esophageal squamous cell carcinoma
Jingrong Xian;Shiwen Wang;Yanyu Jiang;Lihui Li;Lili Cai;Ping Chen;Yue Liu;Xiaofei Zeng;Guoan Chen;Chen Ding;Robert M.Hoffman;Lijun Jia;Hu Zhao;Yanmei Zhang-Department of Laboratory Medicine,Huadong Hospital Affiliated to Fudan University,Shanghai 200040,China;Cancer Institute,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;Research Center on Aging and Medicine,Fudan University,Shanghai 200040,China;Shanghai Key Laboratory of Clinical Geriatric Medicine,Shanghai 200040,China;Department of Basic Science of Oncology,College of Basic Medical Sciences,Zhengzhou University,Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;School of Medicine,Southern University of Science and Technology,Shenzhen 518055,China;State Key Laboratory of Genetic Engineering,Human Phenome Institute,Institutes of Biomedical Sciences,School of Life Sciences,Zhongshan Hospital,Fudan University,Shanghai 200032,China;State Key Laboratory of Cell Differentiation and Regulation,Henan International Joint Laboratory of Pulmonary Fibrosis,Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis,College of Life Science,Institute of Biomedical Science,Henan Normal University,Xinxiang 453007,China;Department of Surgery,University of California,San Diego 92101,USA;Anticancer Inc.,San Diego 92101,USA
Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
Duo Zuo;Yongzi Chen;Xinwei Zhang;Zhuozhi Wang;Wenna Jiang;Fan Tang;Runfen Cheng;Yi Sun;Lu Sun;Li Ren;Rui Liu-Department of Clinical Laboratory;Department of Tumor Cell Biology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;School of Biomedical Engineering,Tianjin Medical University,Tianjin 300070,China;Department of Pathology,Tianjin Huanhu Hospital,Tianjin 300350,China;Department of Pathology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;School of Pharmacy,Tianjin Medical University,Tianjin 300070,China;Department of Gastrointestinal Medical Oncology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
Leyi Yao;Qian Zhao;Ding Yan;Ziying Lei;Yali Hao;Jinghong Chen;Qian Xue;Xiaofen Li;Qingtian Huang;Daolin Tang;Q.Ping Dou;Xin Chen;Jinbao Liu-Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,State Key Laboratory of Respiratory Disease,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;Institute of Digestive Disease of Guangzhou Medical University,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China;School of Public Health,Guangzhou Medical University,Guangzhou,511436,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy
Shen Junyi;Qi Weili;Dai Junlong;Leng Shusheng;Jiang Kangyi;Zhang Yu;Ran Shun;Li Chuan;Wen Tianfu-Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Chengdu University, Chengdu, Sichuan 610072, China;Department of Hepatobiliary and Pancreatic Surgery, The People's Hospital of Leshan, Leshan, Sichuan 614700, China;Department of Hepatobiliary Surgery, Sichuan Provincial People's Hospital, Chinese Academy of Sciences, Chengdu, Sichuan 610072, China;Department of Hepatobiliary Surgery, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou 550000, China
Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1
Li Mingzhe;Zhou Jiaxin;Zhang Zhengkui;Li Jisong;Wang Feng;Ma Ling;Tian Xiaodong;Mao Zebin;Yang Yinmo-Department of General Surgery, Peking University First Hospital, Beijing 100034, China;Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang 310016, China;Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China;Department of Surgical Oncology, Peking University Ninth School of Clinical Medicine (Beijing Shijitan Hospital, Capital Medical University), Beijing 100038, China;Department of Medical Biochemistry and Molecular Biology, Peking University Health Science Center, Beijing 100191, China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。